Table 3 Baseline demographic and clinical characteristics of HF and non-HF patients from validation group
Characteristics | HF patients (n = 7) | Non-HF patients (n = 7) | P value |
|---|---|---|---|
Men | 7 (100%) | 7 (100%) | NA |
Women | 0 (0%) | 0 (0%) | NA |
Age (years) | 59.7 ± 9.4 | 56.7 ± 13.2 | 0.634 |
BMI (kg/m2) | 30 ± 3.7 | 26.1 ± 4.2 | 0.092 |
Hypertension | 5 (71.4%) | 5 (71.4%) | 1 |
Diabetes | 2 (28.6%) | 0 (0%) | 0.462 |
Previous MI | 0 (0%) | 0 (0%) | NA |
Smoking | 3 (42.9%) | 5 (71.4%) | 0.592 |
Hypercholesterolemia | 5 (71.4%) | 5 (71.4%) | 1 |
AMI | 3 (42.9%) | 2 (28.6%) | 1 |
NT-proBNP (pg/mL)a | 1,960.9 ± 3,421.9 | 119.4 ± 118.9 | 0.002 |
LVEF (%)a | 28.9 ± 6.3 | 57.7 ± 4.7 | <0.001 |
Medications | |||
Aspirin | 7 (100%) | 7 (100%) | NA |
Clopidogrel | 7 (100%) | 7 (100%) | NA |
Beta blockers | 7 (100%) | 6 (85.7%) | 1 |
ACE inhibitors | 7 (100%) | 7 (100%) | NA |
Statins | 7 (100%) | 7 (100%) | NA |
Diuretics | 5 (71.4%) | 1 (14.3%) | 0.103 |